Aortech Share Discussion Threads

[langland] 16/6/2020 09:55

Short while ago one could buy 15k at 113 so there must be a trade in the background which has taken out much of the offer volume.

[someuwin] 16/6/2020 09:49

Stock still hard to come by, Can buy £3k online but not £4k.

[bones] 16/6/2020 08:26

Good spot someuwin. As the old advert said,

“The future is bright, the future is RUA!”

[someuwin] 16/6/2020 08:15

New filing gone in at Companies House. So things are moving ahead...

"16 Jun 2020
Resolutions
* Change company name resolution on 2020-06-11
This document is being processed and will be available in 5 days."

[the stigologist] 14/6/2020 00:46

Yes. That sums it up.

[bones] 13/6/2020 22:23

LOL Stig! No, definitely not. To be fair, even you say that the main attraction of, let’s say, AVCT, is the non-Covid side, hence the vast sums they raised for cancer work being the killer app there, as I understand the argument.

[the stigologist] 13/6/2020 21:28

I feel personally attacked

"...while the punters are trying to make a quick buck second guessing the maker of the Covid miracle cure."

[bones] 13/6/2020 16:43

Chart here:


free stock charts from uk.advfn.com

[bones] 13/6/2020 16:35

Something for the weekend? This 10 year chart shows the price approaching an old high resistance level of 130p, a spot it hasn’t been to for nearly 7 years. Prior to that, it had fallen off from around the 375p mark a year or more earlier. These levels preceded the US manufacturing moves, the dispute with St Judes and the abrupt departure of the CEO of the time. It’s been tough for the company to win back investor support ever since then, that is until the heroic new strategy was put in place in 2018. Perhaps the support is coming back now with so much management success and strengthening of the board over the last two years culminating in the RUA acquisition. The name change to RUA Life Sciences should finally consign that long “AorTech”; legacy to the history books and have investors focussing on the future!

[bones] 13/6/2020 11:30

Thanks nimbo10 :) I am sure there must be other factors at work too. The heart valve developments will slowly get out there in time. Aortech is still mainly ignored by the investing world especially while the punters are trying to make a quick buck second guessing the maker of the Covid miracle cure.

I am looking forward to Aortech/RUA’s big push in July with the promise of a new detailed note by Shore Capital along with the planning outlook for the next 12-18 months, as Landy90 highlighted.

Hopefully, by then, the launch of the RUA brand and name change will have happened and it will be “all systems go!”.

[nimbo10] 13/6/2020 11:19

Since Bones' note there seems to have been pretty good buying volume, most notable on 11th a trade for 18600 at 1.16 around 10:20 valued at 21k.
MMs seem to be in accumulation mode.

Some high net worth investors may well be coming on board.

[nimbo10] 13/6/2020 11:19

Since Bones' note there seems to have been pretty good buying volume, most notable on 11th a trade for 18600 at 1.16 around 10:20 valued at 21k.
MMs seem to be in accumulation mode.

Some high net worth investors may well be coming on board.

[bones] 12/6/2020 11:42

Indeed, someuwin. If Medibrane can get “Elast-Eon Enabled” stents and the like into the market through its part-owner and collaboration partner, Resonetics, then take a look at what Resonetics can do globally:



Example: “Resonetics expects to double its number of employees over the next two years. The site operates 24/7 and is focused on high volume component and sub-assembly production for export and for the local medical device industry. Today, more than 16,000 people work in 60 companies in Costa Rica, including 8 of the Top 30 Life Sciences companies worldwide such as Medtronic, Cardinal Health, Philips, Abbott, Edwards Lifesciences, MicroVention, Hologic and Smith & Nephew.“

[someuwin] 12/6/2020 10:02

Good post bones. I'd forgotten about the AOR Medibrane agreement.

The stent market is indeed huge - last time I checked it was forecast to be worth $10 billion per annum by 2025.

[bones] 12/6/2020 09:32

It is encouraging to see that Resonetics, the precision nitinol medical device parts makers are ploughing on with their expansion plans.


In the last couple of years, Resonetics has taken a material stake in Medibrane, an Israeli based maker of polymer coverings for the same devices that Resonetics supplies the metal frames for, eg cardiovascular stents. There seems little doubt that the two companies are combining their respective skills to supply the major device makers of the globe.

Hence why Aortech last year signed a major licensing deal with Medibrane, so that the latter company could start to design polymer covered products such as stents containing Elast-Eon, much the same way as RUA Medical Devices is doing with the products being developed by Aortech.

Recalling the announcement last November (only just over 6 months ago);



Elad Einav, CEO of Medibrane, said: ”We have already trialled the Elast-Eon(TM) material for some applications and found it to have a number of benefits over other polymers with regard to manufacturing process stability as well as cohesiveness. This coupled with the world class biocompatible and biostable properties of Elast-Eon(TM) should allow us to help grow the number of uses for Elast-Eon(TM) in medical devices.”

Bill Brown, Chairman of AorTech, said: ”The AorTech team has been very impressed with Medibrane's technical capabilities and look forward to a long and successful partnership with them. We are delighted to be working with a commercially focused business such as Medibrane to help promote a greater number of Elast-Eon(TM) enabled medical devices.”

This was hailed by Bill later in the Aortech half year report as ”....a very important licence agreement with Medibrane Limited, experts in encapsulation technology for medical devices but stents in particular....”

It takes a long time for new products to be moved through the regulatory processes but I will be intrigued to know how this “very important” licence agreement is progressing. Perhaps we will get an update at the final results next month.

The fact that Resonetics, a key partner of Medibrane, is expanding its operations must bode well. Knowing that Aortech have learned from the mistakes of the distant past, I am confident they will seek full value for their new licensing deals. The fruits of this deal will hopefully emerge in time as and when Elast-Eon enabled stents start to be approved. After all, stents represent a HUGE market!

[someuwin] 12/6/2020 09:27

Can get an online buy quote for £4k. But not for £5k.

[wageslave] 11/6/2020 12:51

Getting bought on dips. Very positive.

[greedy rooster] 11/6/2020 11:42

Fighting back from early markdown, good to see.

[landy90] 10/6/2020 16:51

And hope that the timelines are driven by scientists and R&D engineers not by market expectations.

[bones] 10/6/2020 16:43

Not forgetting Shore Capital comment from last week:

"At that stage, we now also intend to set out a timeline of the potential significant milestones that will be achieved over the coming 12-18 months.“

[someuwin] 10/6/2020 16:24

Coming soon:

Results in July with full update and new comprehensive broker analysis.

Start of testing

Company name change

...The above are known unknowns. The bigger news could well be from the unknown unknowns. i.e I am convinced discussions with 'other parties' are more advanced than we are being told!

[langland] 10/6/2020 13:01

Well I certainly would not buy a second hand heart valve from Foldax!